|
Source – Medi-lexicon - UCB announced positive clinical trial results from a study evaluating Keppra® (levetiracetam) as adjunctive treatment in adult and paediatric patients (4-65 years of age) suffering from idiopathic generalised epilepsy (IGE), with primary generalised tonic-clonic (PGTC) seizures. The results of this phase III, double-blind, multicentre, randomised, placebo-controlled study in 164 patients demonstrated that Keppra® significantly reduced the frequency of PGTC seizures when compared with placebo. Seizures were previously uncontrolled despite treatment with one or two concomitant anti-epileptic drugs.
Keppra® is currently indicated in the UK as adjunctive therapy in the treatment of partial onset seizures with or without secondary
generalisation in adults and children from 4 years of age with epilepsy.
For more information go to:
http://www.pharma-lexicon.com/medicalnews.php?newsid=32831
Prepared by Susan Wileman Medicines Information Technician
Date of Preparation: 1st November 2005
|
